Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

ClinicalTrials.gov ID: NCT02349386

Public ClinicalTrials.gov record NCT02349386. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this clinical study is to evaluate the safety and efficacy of three different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the maintenance of testosterone (T) suppression in men with advanced androgen-sensitive prostate cancer.

Study identification

NCT ID
NCT02349386
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
BHR Pharma, LLC
Industry
Enrollment
34 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2015
Primary completion
Jun 13, 2017
Completion
Jan 9, 2018
Last update posted
Mar 30, 2022

2015 – 2018

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Urological Associates of Southern Arizona Tucson Arizona 85741
South Florida Medical Research Aventura Florida 33180
Advanced Urology Institute Daytona Beach Florida 32114
Adult Pediatric Urology, PC Council Bluffs Iowa 51501
Adult Pediatric Urology, PC Omaha Nebraska 68114
Delaware Valley Urology Voorhees Township New Jersey 08043
AccumetRX Clinical Trials Albuquerque New Mexico 87109
Associated Medical Professionals of NY (AMP of NY) Syracuse New York 13210
Eastern Urological Associates Greenville North Carolina 27834
Urologic Consultants of Southeastern Pennsylvania (UCSEPA) Bala-Cynwyd Pennsylvania 19044
Carolina Urologic Research Center Myrtle Beach South Carolina 29572
Urology Clinics of North Texas Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02349386, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2022 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02349386 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →